HHS Unveils Key Dates for Medicare Drug Price Negotiations

March 6, 2023 by TWN Staff
HHS Unveils Key Dates for Medicare Drug Price Negotiations
(Photo by Sarcifilippo via Pixabay)

WASHINGTON — When the Inflation Reduction Act became law last year, it empowered the Health and Human Services secretary, for the first time ever, to begin negotiating certain prescription drug prices with drug manufacturers. The prices would go into effect in 2026.

On Monday, both the Centers for Medicare & Medicaid Services and the Department of Health and Human Services announced key dates in the process they contend will lower prescription drug prices for millions of seniors and people with disabilities across the country.

The biggest difference in the timelines is the CMS memo details multiple comment opportunities for members of the public, people with Medicare and consumer advocates, pharmaceutical manufacturers, Medicare Advantage and Part D plans, health care providers and pharmacies, and other interested parties.

“We cannot do this important work alone and will engage with the public early and often,” CMS Administrator Chiquita Brooks-LaSure offered by way of explanation. 

“We are proactively seeking feedback and insights from a broad range of interested parties throughout implementation of this historic law,” she said.

Key dates for implementation include:

  • By Sept. 1, 2023, CMS will publish the first 10 Medicare Part D drugs selected for the Medicare Drug Price Negotiation Program.
  • The negotiated maximum fair prices for these drugs will be announced by Sept. 1, 2024, and prices will be in effect starting Jan. 1, 2026.
  • In future years, CMS will select for negotiation 15 more Part D drugs for 2027, 15 more Part B or Part D drugs for 2028, and 20 more Part B or Part D drugs for each year after that, as outlined in the Inflation Reduction Act.

“Public feedback is critical to our ability to successfully implement this law and ensure access to innovative, affordable therapies and treatments,” said Dr. Meena Seshamani, M.D., Ph.D., CMS deputy administrator and director of the Center for Medicare. “Through this detailed timeline, we offer stakeholders the predictability they need to contribute to our implementation efforts. We want the public to know when and how they can make their voices heard on forthcoming policies.”

Provisions of the Inflation Reduction Act already in effect:

  • Free vaccines: Recommended preventive vaccines are free of charge for people with Medicare prescription drug coverage as of Jan. 1, 2023. Most notably, these vaccines include shingles and Tdap. This will provide significant savings for people enrolled in Medicare prescription drug plans, as the shingles vaccine alone can cost up to a few hundred dollars. 
  • Insulin cap: Cost-sharing for a month’s supply of each covered insulin is capped at $35 and there is no deductible for these products for people with Medicare prescription drug coverage as of Jan. 1, 2023. More than a million Medicare beneficiaries with diabetes will benefit from this $35 cost-sharing cap per month’s supply of each covered insulin.
    Currently, nearly a quarter of Medicare beneficiaries taking insulin spend more than $70 a month on insulin.  
  • Rebates required from drug manufacturers’ increasing prices faster than inflation. Manufacturers will need to pay rebates to Medicare if they increase their prices for certain drugs at a rate that exceeds the rate of inflation. The first rebate period began Oct. 1, 2022, in Part D and Jan. 1, 2023, in Part B.
  • ACA subsidies: During Marketplace Open Enrollment this year, more people will qualify for help purchasing affordable high-quality health coverage.  
  • Biosimilars: On Oct.1, 2022, CMS implemented the Medicare Part B payment changes, for certain qualifying biosimilars, to temporarily increase payment to providers who administer these products, in order to encourage price competition and the use of biosimilars and their reference biological products.

A biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference biological product. Many biosimilars are life-saving medicines that treat conditions such as diabetes, cancer and immune disorders.

The goal of this provision is to increase access to biosimilars, as well as to encourage competition between biosimilars and reference biological products, which may, over time, lower drug costs and lead to savings for beneficiaries and Medicare.

The more detailed CMS timeline can be found here.

A+
a-
  • Inflation Reduction Act
  • Medicaid
  • Medicare
  • prescription drug prices
  • In The News

    Health

    Voting

    Medicare

    February 1, 2024
    by Dan McCue
    Administration Makes First Offer in Drug Price Negotiation Process

    WASHINGTON — The Biden-Harris administration on Thursday sent its initial offers to the makers of 10 prescription drugs that have... Read More

    WASHINGTON — The Biden-Harris administration on Thursday sent its initial offers to the makers of 10 prescription drugs that have been selected for price negotiations with Medicare under the Inflation Reduction Act. Medicare is federal health insurance for anyone 65 and older, and some people under... Read More

    October 16, 2023
    by Dan McCue
    HHS, Pfizer, Reach Agreement to Ensure Access to Paxlovid

    WASHINGTON — The Department of Health and Human Services announced last week that it has reached an agreement with Pfizer... Read More

    WASHINGTON — The Department of Health and Human Services announced last week that it has reached an agreement with Pfizer to ensure continued patient access to the antiviral Paxlovid as it prepares to transition the COVID treatment to the commercial market. “This agreement builds on HHS... Read More

    October 3, 2023
    by Dan McCue
    Pharma Firms Agree to Participate in Medicare Price Negotiations

    WASHINGTON — The White House announced Tuesday that all 10 drug companies whose products were selected for price negotiations with... Read More

    WASHINGTON — The White House announced Tuesday that all 10 drug companies whose products were selected for price negotiations with Medicare have agreed to participate in those talks. The companies, which include Bristol Myers Squibb, the maker of Eliquis, Boehringer Ingelheim, maker of Jardiance, and Janssen... Read More

    Biden's Medicare Price Negotiation Push Is Broadly Popular. He's Not Getting Much Credit

    WASHINGTON (AP) — President Joe Biden is trumpeting Medicare's new powers to negotiate directly with drugmakers on the cost of prescription medications — but... Read More

    WASHINGTON (AP) — President Joe Biden is trumpeting Medicare's new powers to negotiate directly with drugmakers on the cost of prescription medications — but a poll shows that any immediate political boost that Biden gets for enacting the overwhelmingly popular policy may be limited. Three-quarters of Americans, or 76%, favor... Read More

    Biden Targets Diabetes Drug Jardiance and Nine Others for Medicare Price Talks

    WASHINGTON (AP) — The Biden administration is targeting the blood thinner Eliquis, diabetes treatment Jardiance and eight other medications for... Read More

    WASHINGTON (AP) — The Biden administration is targeting the blood thinner Eliquis, diabetes treatment Jardiance and eight other medications for Medicare's first-ever drug price negotiations as it seeks to lower medical costs for Americans. The administration on Tuesday released a list of the 10 drugs for which prices... Read More

    Biden Launches New Push to Limit Health Care Costs

    WASHINGTON (AP) — President Joe Biden on Friday rolled out a new set of initiatives to reduce health care costs:... Read More

    WASHINGTON (AP) — President Joe Biden on Friday rolled out a new set of initiatives to reduce health care costs: a crackdown on scam insurance plans, new guidance to prevent surprise medical bills and an effort to reduce medical debt tied to credit cards. Biden's remarks... Read More

    News From The Well
    scroll top